Are medical device companies quietly exploiting the AI regulatory blind spot — and are we heading toward a wave of recalls because of it?
Genuine question for anyone working in regulatory affairs, medical devices, or compliance.
I come from market research and data analytics, so I think a lot about how decisions get made, and where the gaps between intention and execution show up.
Here’s the pattern I keep coming back to:
AI is being pushed hard across industries for efficiency and speed. Regulatory frameworks for AI-enabled medical devices are still being written. Health Canada, FDA, and EU regulators are all moving at different speeds and not always in sync.
And quietly, a lot of companies are eliminating senior regulatory affairs professionals from their org charts. Replacing them with legal teams, AI tools, or just not replacing them at all.
On paper that looks like cost optimization. But I wonder if something else is happening.
Here’s the sequence I keep seeing:
Senior RA professionals get asked to train offshore or international teams, junior staff in lower cost markets, to handle regulatory documentation, submission prep, and compliance monitoring. The knowledge transfer happens. The offshore team is up and running. And then the senior positions get eliminated.
It’s not unique to regulatory affairs. But in a field where judgment matters as much as process knowledge, it’s a particularly dangerous move. You can transfer the workflow. You can’t transfer 20 years of reading between the lines of a Health Canada guidance document, or knowing when a submission is technically compliant but likely to trigger a follow-up.
Senior RA people are expensive. Their value is invisible until something goes wrong. If you remove them during a period of regulatory ambiguity when the frameworks are still loose and enforcement is inconsistent. You create a window. Lower compliance friction. Faster time to market. Higher short term revenue.
And sales-driven leadership knows this.
The risk is real though. AI models drift. Post-market surveillance without experienced oversight misses signals early. Offshore teams trained on yesterday’s frameworks are navigating today’s moving targets without the institutional knowledge to know what’s changed and why. And when the regulatory frameworks do catch up, and they will. The gap between what was sold and what was actually validated is going to be hard to hide.
Recalls are expensive. Enforcement actions are public. Brand damage in healthcare takes years to recover from.
So my questions for people actually inside this space:
Is this pattern real or am I reading too much into it? Are companies knowingly taking this risk for short term revenue?
Are you seeing the offshore training and eliminate model play out in your organization or industry?
And, do you think we’re heading toward a wave of recalls driven by AI augmentation, cost cutting, and the regulatory blind spot it’s all creating?
Would genuinely love to hear from people closer to this than I am.